A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor
Primary Purpose
Cystic Fibrosis
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Measurement of Sweat Chloride and Sweat Bromide
Sponsored by
About this trial
This is an interventional diagnostic trial for Cystic Fibrosis
Eligibility Criteria
Inclusion Criteria:
- Adults 18 years of age or older capable of providing written informed consent AND
- Patients with an established diagnosis of Cystic Fibrosis (CF) OR Healthy volunteers
Exclusion Criteria:
- Participants under medications or with disorders known to cause a positive error in the sweat test will be excluded in the study. Common causes of positive error in sweat test are mineralocorticoid hormone therapy, adrenal insufficiency, glycogen storage diseases, hypothyroidism, hypoparathyroidism, nephrogenic diabetes insipidus, G6PD deficiency or ectodermal dysplasia OR
- Any other skin or soft tissue disorders that could affect obtaining the necessary volumes of sweat.
Sites / Locations
- Penn State Milton S. Hershey Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Subjects with Cystic Fibrosis
Healthy Volunteers
Arm Description
Diagnostic
Diagnostic
Outcomes
Primary Outcome Measures
Sweat chloride measurements in sweat samples via ion exchange chromatography
Sweat specimen samples obtained via pilocarpine iontophoresis will be measured for sweat chloride. Measurements for chloride will be determined by ion exchange chromatography measured in millimolar (mM).
Sweat chloride measurements in sweat samples via fluorescence quenching
Sweat specimen samples obtained via pilocarpine iontophoresis will be measured for sweat chloride. Measurements for the chloride will be determined by fluorescence citrate-based sensors, measured in millimolar (mM).
Sweat bromide measurements in sweat samples via fluorescence quenching
Sweat specimen samples obtained via pilocarpine iontophoresis will be measured for sweat bromide. Measurements for bromide will be determined by fluorescence citrate-based sensors, measured in millimolar (mM).
Secondary Outcome Measures
Full Information
NCT ID
NCT03367494
First Posted
November 22, 2017
Last Updated
June 20, 2022
Sponsor
Milton S. Hershey Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT03367494
Brief Title
A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor
Official Title
A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Terminated
Why Stopped
Investigator Decision
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
June 1, 2020 (Actual)
Study Completion Date
December 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Milton S. Hershey Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cystic Fibrosis (CF) is a hereditary multi-system disease affecting approximately 30,000n children and adults in the USA. The diagnosis of CF requires biochemical confirmation (either abnormal sweat chloride measurement and/or identification of two CF disease causing mutations) plus clinical symptomatology. Measurements of sweat chloride remain cumbersome and although most common methodology to confirm CF diagnosis with limitations especially in young children less than 6 months of age and in areas that lack ability for the complex testing. The study objectives of this current research proposal include: A) To expand upon previously obtained pilot study data "Evaluation of a fluorescent-based chloride sensor as an optical sweat test to diagnose cystic fibrosis" B) To add the exploratory measurement of sweat Bromide as a first in human assessment observation, C) To Evaluate the development of smartphone based point-of-care technology for chloride and bromide sensor measurements, D) To further expand the class of citrate-based sensors with improved fluorescence and sensing properties for the design of new fluorescence-based analytical and diagnostic solutions based on the automated multi-halide detection system, and E) To develop point-of-care systems that can successfully integrate into clinical settings to improve current practices and facilitate early detection of disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Subjects with Cystic Fibrosis
Arm Type
Other
Arm Description
Diagnostic
Arm Title
Healthy Volunteers
Arm Type
Other
Arm Description
Diagnostic
Intervention Type
Diagnostic Test
Intervention Name(s)
Measurement of Sweat Chloride and Sweat Bromide
Intervention Description
Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
Primary Outcome Measure Information:
Title
Sweat chloride measurements in sweat samples via ion exchange chromatography
Description
Sweat specimen samples obtained via pilocarpine iontophoresis will be measured for sweat chloride. Measurements for chloride will be determined by ion exchange chromatography measured in millimolar (mM).
Time Frame
anticipated 12 months
Title
Sweat chloride measurements in sweat samples via fluorescence quenching
Description
Sweat specimen samples obtained via pilocarpine iontophoresis will be measured for sweat chloride. Measurements for the chloride will be determined by fluorescence citrate-based sensors, measured in millimolar (mM).
Time Frame
anticipated 12 months
Title
Sweat bromide measurements in sweat samples via fluorescence quenching
Description
Sweat specimen samples obtained via pilocarpine iontophoresis will be measured for sweat bromide. Measurements for bromide will be determined by fluorescence citrate-based sensors, measured in millimolar (mM).
Time Frame
anticipated 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adults 18 years of age or older capable of providing written informed consent AND
Patients with an established diagnosis of Cystic Fibrosis (CF) OR Healthy volunteers
Exclusion Criteria:
Participants under medications or with disorders known to cause a positive error in the sweat test will be excluded in the study. Common causes of positive error in sweat test are mineralocorticoid hormone therapy, adrenal insufficiency, glycogen storage diseases, hypothyroidism, hypoparathyroidism, nephrogenic diabetes insipidus, G6PD deficiency or ectodermal dysplasia OR
Any other skin or soft tissue disorders that could affect obtaining the necessary volumes of sweat.
Facility Information:
Facility Name
Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
No personally identifiable information will be communicated to investigators at PSU-University Park. Sweat samples will be identified solely by code which code will be linked to personally identifiable information known only to Dr. Vender and which code will be kept in a locked office at Hershey Medical Center (HMC) Biomedical Research Building C5860. This code will contain participant (both CF patients and healthy volunteers): name, HMC medical record #, age, gender, date of sample, date of birth and sweat chloride/bromide results. In the event of any publication or presentation resulting from the research, no personally identifiable information will be shared. Personally identifiable health information access (such as diagnosis, name, HMC medical record#, age, gender, date of birth) is specifically for Cystic Fibrosis patients. Medical records and health information will NOT be accessed for healthy control volunteers, however name, age, gender, date of birth will be recorded.
Citations:
PubMed Identifier
28595077
Citation
Zhang C, Kim JP, Creer M, Yang J, Liu Z. A smartphone-based chloridometer for point-of-care diagnostics of cystic fibrosis. Biosens Bioelectron. 2017 Nov 15;97:164-168. doi: 10.1016/j.bios.2017.05.048. Epub 2017 May 27.
Results Reference
background
PubMed Identifier
28348728
Citation
Kim JP, Xie Z, Creer M, Liu Z, Yang J. Citrate-based fluorescent materials for low-cost chloride sensing in the diagnosis of Cystic Fibrosis. Chem Sci. 2017 Jan 1;8(1):550-558. doi: 10.1039/C6SC02962K. Epub 2016 Aug 30.
Results Reference
background
Learn more about this trial
A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor
We'll reach out to this number within 24 hrs